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Letter to the Editors-in-Chief
COVID-19 and thrombotic complications: Pulmonary thrombosis rather than embolism?
Dear Editor,
We read with great interest the recent article by Demelo-Rodríguez
et al., reporting that the incidence of (asymptomatic) deep vein
thrombosis (DVT) in patients admitted with COVID-19 pneumonia
(14.7%) was not greater than that described in other series of non-
COVID affected patients admitted to general medicine or orthopedic
wards [1]. Recent studies have reported a high number of venous
thrombotic complications in patients with pneumonia related to SARS-
CoV2 infection admitted to ICU or general wards, despite standard
prophylactic anticoagulation [2–4]. Most were pulmonary events
(presumed pulmonary embolism [PE]) [2,3], which were much more
common in COVID-19 patients than in other groups of patients with
respiratory failure from other etiologies [2].
Interestingly, the majority of patients with PE did not have asso-
ciated DVT [2,4]. Of note, recent autopsy studies [5] were consistent
with thrombosis occurring within the pulmonary arterial circulation, in
the absence of apparent embolism.
These data suggest that COVID-19 may be associated with a high
incidence of pulmonary thrombosis (PT) rather than of venous throm-
boembolism. PT is not a new entity or a distinctive feature of COVID-
19; it has been found also in patients with respiratory failure from other
causes, both infectious and non-infectious [6]. However, it seems more
common in COVID-19 [2–4].
Local thrombi may form in the lung vessels as a consequence of
strong activation of inflammatory processes within the lung, with as-
sociated cytokine storm and resultant pulmonary endothelial dysfunc-
tion or damage. In addition, SARS-CoV-2 could activate the coagulation
pathway by binding the ACE-2 receptor of type II pneumocytes and
then dysregulating the kallikrein/kinin system [7]. The high incidence
of PT could also be the result of a prothrombotic state associated with
the presence of lupus anticoagulant (LA), detected in about 90% of the
tested patients in a recent study [2].
If confirmed, these speculations could have two practical con-
sequences. First, if COVID-19 is associated with PT rather than PE, the
commonly used Wells pretest probability score may not be valid since it
depends on the presence/absence of clinical signs of DVT, which would
not be relevant for in situ PT. Second, the different pathogenic me-
chanism of PT from PE may alter treatment recommendations. The
available literature suggests that standard prophylactic therapy with
LMWH is not able to prevent pulmonary thrombotic complications in
COVID-19 patients. This finding could be the consequence of different
pathogenic mechanisms behind PT and PE. If confirmed, it could take to
change the use of anticoagulants in these patients: to start with higher
prophylactic or directly therapeutic doses of LMWH since admission,
and to consider a prolonged administration of anticoagulants after
hospital discharge.
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